International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 001-008
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |
Factors Affecting Bladder Dose in Gynecologic Intracavitary Brachytherapy
Mustafa ADLI1, Melahat GARİPAĞAOĞLU2, Zafer KOÇAK3, M. Faruk KÖSE4, Cengiz KURTMAN5
1Gaziantep Üniversitesi Tıp Fakültesi, Radyasyon Onkolojisi Anabilim Dalı, GAZİANTEP
2Acıbadem Hastanesi Radyasyon Onkolojisi, İSTANBUL
3Trakya Üniversitesi Tıp Fakültesi, Radyasyon Onkolojisi Anabilim Dalı, EDİRNE
4SSK Sağlık Bakanlığı Etlik Kadın Doğum Hastanesi Jinekolojik Onkoloji Bölümü, ANKARA
5Ankara Üniversitesi Tıp Fakültesi, Radyasyon Onkolojisi Anabilim Dalı, ANKARA
Keywords: Gynecologic intracavitary brachytherapy, Bladder dose, ICRU, Surgery
The purpose of this study is to investigate factors affecting bladder ICRU reference point dose in gynecologic cancer patients receiving intracavitary brachytherapy. Forty seven different intracavitary HDR brachytherapy applications were performed using tandem-ovoid (n=25), vaginal ovoid (n=17) and tandem-cylinder (n=5) in 43 patients diagnosed with cervical (n=29), endometrial (n=12) and vaginal (n=2) carcinoma. Effect of applicator type, number of pregnancy and delivery, and type of hysterectomy in operated patients on ICRU bladder reference point dose was investigated. ICRU bladder reference point dose was significantly higher in tandem-cylinder applications than in vaginal ovoid alone or tandem-ovoid applications (p=0.009). No difference was found between vaginal ovoid alone and tandem- ovoid applications. Number of pregnancy and delivery had no effect on bladder dose. Bladder reference point dose was significantly higher in patients underwent type 3 hysterectomy compared to type 1-2 hysterectomy (p<0.001). Several factors affect bladder dose during gynecologic intracavitary brachytherapy. Patient and applicator related factors should be evaluated together and any necessary changes needed should be made in the treatment plan accordingly.
Mustafa ADLI1, Melahat GARİPAĞAOĞLU2, Zafer KOÇAK3, M. Faruk KÖSE4, Cengiz KURTMAN5
1Gaziantep Üniversitesi Tıp Fakültesi, Radyasyon Onkolojisi Anabilim Dalı, GAZİANTEP
2Acıbadem Hastanesi Radyasyon Onkolojisi, İSTANBUL
3Trakya Üniversitesi Tıp Fakültesi, Radyasyon Onkolojisi Anabilim Dalı, EDİRNE
4SSK Sağlık Bakanlığı Etlik Kadın Doğum Hastanesi Jinekolojik Onkoloji Bölümü, ANKARA
5Ankara Üniversitesi Tıp Fakültesi, Radyasyon Onkolojisi Anabilim Dalı, ANKARA
Keywords: Gynecologic intracavitary brachytherapy, Bladder dose, ICRU, Surgery
The purpose of this study is to investigate factors affecting bladder ICRU reference point dose in gynecologic cancer patients receiving intracavitary brachytherapy. Forty seven different intracavitary HDR brachytherapy applications were performed using tandem-ovoid (n=25), vaginal ovoid (n=17) and tandem-cylinder (n=5) in 43 patients diagnosed with cervical (n=29), endometrial (n=12) and vaginal (n=2) carcinoma. Effect of applicator type, number of pregnancy and delivery, and type of hysterectomy in operated patients on ICRU bladder reference point dose was investigated. ICRU bladder reference point dose was significantly higher in tandem-cylinder applications than in vaginal ovoid alone or tandem-ovoid applications (p=0.009). No difference was found between vaginal ovoid alone and tandem- ovoid applications. Number of pregnancy and delivery had no effect on bladder dose. Bladder reference point dose was significantly higher in patients underwent type 3 hysterectomy compared to type 1-2 hysterectomy (p<0.001). Several factors affect bladder dose during gynecologic intracavitary brachytherapy. Patient and applicator related factors should be evaluated together and any necessary changes needed should be made in the treatment plan accordingly.
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |